Truist raised the firm’s price target on Disc Medicine (IRON) to $114 from $86 and keeps a Buy rating on the shares. The firm is updating its model to incorporate Disc’s Q3 financial results, the full U.S. bitopertin opportunity in EPP, and an accelerated launch timeline following receipt of the FDA Commissioner’s priority review vouchers, the analyst tells investors in a research note.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRON:
- Disc Medicine: Strong Financial Position and Promising Product Pipeline with Bitopertin’s Billion-Dollar Potential
- Disc Medicine Advances Pipeline Amid Financial Growth
- Disc Medicine’s Promising Pipeline and Regulatory Advancements Justify Buy Rating
- Disc Medicine reports Q3 EPS ($1.77), consensus ($1.47)
- Disc Medicine resumed with a Buy at Stifel